Når Magnus Heunicke siger vores - så mener han regeringens

Logo for hæmatologisk tidsskrift

- først med nyheder om medicin

Yngre forskere anerkendt af ASH med priser

ASH: Det amerikanske selskab for hæmatologi, ASH, anerkender en række yngre forskere, hvis abstracts modtager en af priserne i ASH Abstract Achievement Award-programporteføljen på ASH's årsmøde i Orlando, USA.

"Jeg er begejstret over at anerkende disse talentfulde forskere i den tidlige karriere for deres fremragende bidrag til hæmatologien. At kunne præsentere deres arbejde på det årlige møde er en utrolig mulighed for dem for at få anerkendelse for deres hårde arbejde og for at udvikle deres karriere," siger ASH's formand Roy Silverstein fra Medical College of Wisconsin i Milwaukee, USA, i en pressemeddelelse.

Modtagerne af The 2019 Outstanding Abstract Achievement Award, som bliver præsenteret på  Special Symposium on the Basic Science of Hemostasis and Thrombosis mandag den 9. december kl. 16.30-18.30 amerikansk tid, er:

Undergraduate Student:
Stacy B. Kiven, BS
University of Minnesota, Minneapolis, MN
Abstract 76
Calpain-1 Contributes to Pain and Organ Damage in Sickle Cell Disease

Medical Student
Hrishikesh Srinagesh, BA
Icahn School of Medicine at Mount Sinai, New York, NY
Abstract 367
The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease

Graduate Student
Melanie Castro-Mollo, MD
Icahn School of Medicine at Mount Sinai, New York, NY
Abstract 2
Erythroferrone Regulates Bone Remodeling in β-Thalassemia

Resident Physician
Naranie Shanmuganathan, MBBS, FRACP, FRCPA
Royal Adelaide Hospital and SA Pathology, Adelaide, Australia
Abstract 662
RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML

Post-Doctoral Fellow
Tomoya Muto, MD PhD
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Abstract 727
Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity

En anden pris, der vil blive uddelt på ASH's årsmøde, er Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis. Den anerkender en studerende eller post doc, som er førsteforfatter på et af de højest scorede abstracts indsendt til ASH's årsmøde på feltet for hæmostase og trombese. Modtagerne af årets pris er:

Oluwatoyosi Muse, PhD
Beth Israel Deaconess Medical Center, Boston, MA
Abstract 632
The Unfolded Protein Response Causes Prothrombotic Transformation of Pancreatic Cancer Linking Tumor Progression with Cancer-Associated Thrombosis

Modtagerne af ASH-International Paroxysmal Interest Group Abstract Achievement Award for Paroxysmal Nocturnal Hemoglobinuria 2019 er:

Hassan Awada, MD
Cleveland Clinic, Cleveland, Ohio
Abstract 2499
Molecular Characterization of Leukemia Evolving from Paroxysmal Nocturnal Hemoglobinuria

Tanabe Mikoto, MD
Kanazawa University, Kanazawa, Japan
Abstract 3736
A GPI-Anchored Protein, CD109, Protects Hematopoietic Progenitor Cells from Erythroid Differentiation Induced By TGF-β.

Giuseppe Bigi Memorial Award uddeles til en italiensk yngre forsker på en italiensk institution, som har et af de højest scorede abstracts indsendt på feltet for hæmostase og stamceller. Årets modtager er:

Marilena Ciciarello, PhD
Azienda Ospedaliero-Universitaria S. Orsola- Malphighi, Bologna, Italy
Abstract 1212
Interferon-γ-Dependent Inflammatory Signature in Acute Myeloid Leukemia Cells Is Able to Shape Stromal and Immune Bone Marrow Microenvironment

Modtageren af Giuseppe Bigi Abstract Achievement Award er:

Annamaria April, PhD-IRCCS
San Raffaelle Scientific Institute, Milano, Italy
Abstract 967
Hematopoietic Stem Cell Function in β-Thalassemia Is Impaired and Is Rescued By Targeting the Bone Marrow Niche

Modtagerne af ASH-British Society of Haematology Abstract Achievement Award er:

Sam Alimam, DHCS, MD 
King’s College London, London, United Kingdom
Abstract 308
Molecular, Epigenetic and Gene Expression Profiling of Triple Negative Essential Thrombocythaemia

Claire Burney, MBBS
University Hospitals Bristol, Bristol, United Kingdom
Abstract 701
Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 – a Retrospective Study from the LWP-EBMT

Konstantinos Tzelepis, PhD
University of Cambridge, Cambridge, United Kingdom
Abstract 403
Pharmacological Inhibition of the RNA m6a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Modtageren af ASH-Haematology Society of Australia and New Zealand Abstract Achievement Award er:

Chong Chyn Chua, MBBS, FRACP, FRCPA
The Alfred Hospital and Monash University, Melbourne, Australia
Abstract 462
Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study.

Modtagerne af ASH-Japanese Society of Hematology Abstract Achievement Award er:

Takeshi Fujino, MD
University of Tokyo, Tokyo, Japan
Abstract 821
Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment

Haruko Shima, MD, PhD
Keio University School of Medicine, Tokyo, Japan
Abstract 25
Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)

Koya Ono, MD
Tohoku University Graduate School of Medicine, Sendai, Japan
Abstract 3530
Molecular Characterization and Novel Therapeutic Strategy for X-Linked Siderblastic Anemia Associated with ALAS2 Missense Variants

Modtagerne af ASH-Society Italiana di Ematologia Abstract Achievement Award er:

Chiara Magnani, PhD
University of Milano-Bicocca/Fondazione MBBM, Milano, Italy
Abstract 200
Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Pier Edoardo Rovatti, MD
IRCCS San Raffaele Scientific Institute, Milano, Italy
Abstract 513
Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Hvert år uddeler ASH desuden den merit-baserede Minority Graduate Student Abstract Achievement Award, som udvælger sidsteårsstuderende for at hædre deres forskningsresultater samt rekruttere underrepræsenterede minoritetsstuderende på deres felt inden for hæmatologi. Årets modtagere er:

Adedamola Elujoba-Bridenstine, MS
University of Illinois at Chicago, Chicago, Illinois
Abstract 3707
The Neurotransmitter Receptor Gabbr1 Regulates Proliferation and Function of Hematopoietic Stem and Progenitor Cells

Marcus Florez, BS
Baylor College of Medicine, Houston, TX
Abstract 3726
IFNy Stimulation Induces Hematopoietic Stem Cell Homing and Niche Relocalization

Mohammed Gbadamosi, BS
University of Florida College of Pharmacy, Gainesville, FL
Abstract 908
Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms

Jamie Hamilton, BS
Emory University, Atlanta, GA
Abstract 1468
Elevated Levels of Interleukin-9 in Obese Microenvironments Promote Leukemia Progression and Chemoresistance in B-Cell Acute Lymphoblastic Leukemia Cells

Joseph Krambs, BS
Washington University School of Medicine, St. Louis, MO
Abstract 1209
Canonical Signaling By TGF Family Members in Mesenchymal Stromal Cells Is Dispensable for Hematopoietic Niche Maintenance Under Basal and Stress Conditions

Emaan Madany, BS
Cedars-Sinai Medical Center, Los Angeles, CA
Abstract 716
Increased Expression of Type 1 Interferon Stimulated Genes in Sickle Cell Disease and a Potential Association with RBC Alloimmunization

Udskriv Email

Medicinrådet vender tommelfingeren opad til Adcetris

Medicinrådet har anbefalet antistoflægemiddelkonjugatet Adcetris (brentuximab vedotin) kombineret med cyclophosphamid, doxorubicin og prednisolon til patienter med tidligere ubehandlet systemisk anaplastisk storcellet T-cellelymfom (sALCL), som ikke kandiderer til højdosiskemoterapi og stamcelletransplantation.

Læs mere ...

Udskriv Email

Polivy plus bendamustin og rituximab afvist som behandling af visse DLBCL-patienter

Medicinrådet har valgt ikke at anbefale antistoflægemiddelkonjugatet Polivy (polatuzumab vedotin) plus bendamustin og rituximab til behandling af den subgruppe af patienter med recidiverende/refraktær diffust storcellet B-cellelymfom (DLBCL), som ikke kandiderer til højdosiskemoterapi og stamcelletransplantation.

Læs mere ...

Udskriv Email

Nyheder fra Medicinske Tidsskrifter

MS Tidsskrift

Diagnostisk Tidsskrift